Literature DB >> 10494779

Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets--definition and detection of ticlopidine/clopidogrel effects.

U R Schwarz1, J Geiger, U Walter, M Eigenthaler.   

Abstract

Increased platelet adhesion or aggregation are key events in the pathogenesis of cardiovascular diseases. Exact determination of the platelet activation state is essential to recognize, prevent, and treat cardiovascular complications due to platelet dysfunction. Initial phases of platelet activation and inhibition are characterized by phosphorylation of specific intracellular proteins. However, methodological problems often prevent analysis of platelet protein phosphorylation under clinical conditions. A novel flow cytometry-based method using a phosphorylation-specific antibody was developed for fast and easy quantification of the phosphorylation state of a specific intracellular platelet protein. This method was used to analyze various platelet receptors and their intracellular signaling which may be impaired in genetic or acquired disorders or altered due to therapeutic interventions. In a first clinical application, the inhibitory effects of ticlopidine and clopidogrel on the platelet P2YAC ADP receptor were monitored.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10494779

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  38 in total

Review 1.  [Significance of platelet function tests].

Authors:  Z Wolf; H Mani; E Lindhoff-Last
Journal:  Internist (Berl)       Date:  2010-09       Impact factor: 0.743

Review 2.  International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy.

Authors:  Maria P Abbracchio; Geoffrey Burnstock; Jean-Marie Boeynaems; Eric A Barnard; José L Boyer; Charles Kennedy; Gillian E Knight; Marta Fumagalli; Christian Gachet; Kenneth A Jacobson; Gary A Weisman
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

3.  Comparison of the effects of pretreatment with tirofiban, clopidogrel or both on the inhibition of platelet aggregation and activation in patients with acute coronary syndromes.

Authors:  Emilia Solinas; Giuliana Gobbi; George Dangas; Roxana Mehran; Martin Fahy; Luigi Ippolito; Maria Giulia Bolognesi; Ruben Ruenes; Piera Angelica Merlini; Diego Ardissino; Marco Vitale
Journal:  J Thromb Thrombolysis       Date:  2007-11-30       Impact factor: 2.300

4.  State of the art in platelet function testing.

Authors:  Beate E Kehrel; Martin F Brodde
Journal:  Transfus Med Hemother       Date:  2013-03-18       Impact factor: 3.747

5.  The P2Y(12) receptor as a target of antithrombotic drugs.

Authors:  Stephen O'Connor; Gilles Montalescot; Jean-Philippe Collet
Journal:  Purinergic Signal       Date:  2011-06-28       Impact factor: 3.765

Review 6.  Platelets as crucial partners for tumor metastasis: from mechanistic aspects to pharmacological targeting.

Authors:  Annalisa Contursi; Angela Sacco; Rosalia Grande; Melania Dovizio; Paola Patrignani
Journal:  Cell Mol Life Sci       Date:  2017-05-09       Impact factor: 9.261

Review 7.  Monitoring aspirin and clopidogrel response: testing controversies and recommendations.

Authors:  Athanasios Karathanos; Tobias Geisler
Journal:  Mol Diagn Ther       Date:  2013-06       Impact factor: 4.074

8.  Selective and rapid monitoring of dual platelet inhibition by aspirin and P2Y12 antagonists by using multiple electrode aggregometry.

Authors:  Sandra M Penz; Isabell Bernlochner; Orsolya Tóth; Reinhard Lorenz; Andreas Calatzis; Wolfgang Siess
Journal:  Thromb J       Date:  2010-05-13

9.  Historical lessons in translational medicine: cyclooxygenase inhibition and P2Y12 antagonism.

Authors:  Desmond J Fitzgerald; Garret A Fitzgerald
Journal:  Circ Res       Date:  2013-01-04       Impact factor: 17.367

10.  Non-Carriers of Reduced-Function CYP2C19 Alleles are Most Susceptible to Impairment of the Anti-Platelet Effect of Clopidogrel by Proton-Pump Inhibitors: A Pilot Study.

Authors:  Jen-Kuang Lee; Cho-Kai Wu; Jyh-Ming Juang; Chia-Ti Tsai; Juey-Jen Hwang; Jiuun-Lee Lin; Fu-Tien Chiang
Journal:  Acta Cardiol Sin       Date:  2016-03       Impact factor: 2.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.